2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Advance Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Research Snapshot Theater: Pulmonary, Pediatric III

Intrapulmonary Percussive Ventilation (IPV) and Lung Compliance in Invasively Ventilated Children

Tuesday, March 24, 2026
11:15 AM - 12:15 PM Central Time
Location: Connections Central - RST 13
  • AC

    Alexandra Cummings, DO

    New York

    Disclosure(s): No relevant financial relationship(s) to disclose.

  • LS

    Layne Silver, MD

    Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
    Cohen Children's Medical Center, New York

    Disclosure information not submitted.

  • AS

    Alice Shanklin, MD

    Cohen Children's Medical Center

    Disclosure information not submitted.

  • TS

    Todd Sweberg, MBA, MD

    MD
    Cohen Children's Medical Center

    Disclosure information not submitted.

Introduction: Intrapulmonary percussive ventilation (IPV) is an airway clearance therapy (ACT) that delivers high frequency, low tidal volume percussive breaths to facilitate lung recruitment, mobilize secretions, improve gas exchange, and treat and prevent atelectasis. While studies support its safety, efficacy, and benefit, few have described its impact on lung physiology during invasive mechanical ventilation (IMV). This study aims to assess the effect of IPV on lung compliance in a heterogeneous group of invasively ventilated children. We hypothesized that lung compliance would improve following a single treatment.


Methods: This is an ongoing single center, prospective observational pilot study in a 37-bed PICU. Patients ≤18 years old on conventional IMV and receiving IPV as per the clinical team are eligible for inclusion. The primary outcome is dynamic compliance (Cdyn) and secondary outcome is static compliance (Cstat), whenever attainable. Subjects are enrolled within 24 hours of initiating IPV, and compliance is measured 15 minutes before, 15 minutes after, and 3 hours after a treatment.


Results: This interim analysis includes 19 patients with a median age of 6.9 years. 21% were previously healthy, while the remainder had comorbidities, most commonly a neurologic disorder (53%). 11 had cuffed endotracheal tubes and 8 had tracheostomies (7 cuffed). 5 met criteria for pediatric acute respiratory distress syndrome (PARDS). 90% were prescribed additional ACTs, most commonly albuterol (88%), 3% saline (65%), and ipratropium (41%), and 53% were co-administered with IPV.

There was no significant percent change from baseline Cdyn at 15 minutes (5.5%, p=0.246) or 3 hours (5.8%, p=0.353), nor was there a difference within the PARDS subgroup at 15 minutes (12.9%, p=0.125). We also found no difference in Cstat at 15 minutes (10.1%, p=0.25) or 3 hours (7.8%, p=0.50).


Conclusions: This interim analysis does not show a significant improvement in lung compliance following a single IPV treatment in a heterogeneous group of invasively ventilated children, although differences may not have been detected due to small sample size. It is also possible that changes in compliance would be more appreciable with multiple IPV treatments over time.